Firouzeh Gholampour, Susan Abbasi, Zeinab Karimi
Department of Biology, College of Science, Shiraz University, Shiraz, Iran.
Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Curr Res Pharmacol Drug Discov. 2024 Sep 17;7:100201. doi: 10.1016/j.crphar.2024.100201. eCollection 2024.
Hyperglycemia-induced oxidative stress is a significant contributor to diabetic complications, including hepatopathy. The current survey aimed to evaluate the ameliorative effect of quercetin (Q) on liver functional disorders and tissue damage developed by diabetes mellitus in rats.
Grouping of 35 male Wistar rats was performed as follows: sham; sham + quercetin (sham + Q: quercetin, 50 mg/kg/day in 1 ml 1% DMSO for 6 weeks, by gavage); diabetic control (Diabetes: streptozotocin (STZ), 65 mg/kg, i.p.); diabetic + quercetin 1 (D + Q1: quercetin, 25 mg/kg/day in 1 ml 1% DMSO for 6 weeks, by gavage after STZ injection); and diabetic + quercetin 2 (D + Q2: quercetin, 50 mg/kg/day in 1 ml 1% DMSO for 6 weeks, by gavage after STZ injection). Body weight, food intake, and water intake were measured. Ultimately, the samples of plasma and urine, as well as tissue samples of the liver and pancreas were gathered for later assays.
STZ injection ended in elevated plasma blood glucose levels, decreased plasma insulin levels, liver dysfunction (increased activity levels of AST, ALT, and ALP, increased plasma levels of total bilirubin, cholesterol, LDL, triglyceride, decreased plasma levels of total protein, albumin and HDL), enhanced levels of malondialdehyde, diminished activities of antioxidant enzymes (superoxide dismutase, and catalase), reduced level of glutathione (GSH) increased gene expression levels of apelin and TGF-ꞵ, plus liver histological destruction. All these changes were diminished by quercetin. However, the measure of improvement in the D + Q2 group was higher than that of the D + Q1 group.
Quercetin improved liver function after diabetes mellitus type 1, possibly due to reduced lipid peroxidation, increased antioxidant systems, and inhibiting the apelin/TGF-ꞵ signaling pathway.
高血糖诱导的氧化应激是包括肝病在内的糖尿病并发症的重要促成因素。本研究旨在评估槲皮素(Q)对糖尿病大鼠肝功能障碍和组织损伤的改善作用。
将35只雄性Wistar大鼠分组如下:假手术组;假手术+槲皮素组(假手术+Q:槲皮素,50mg/kg/天,溶于1ml 1%二甲基亚砜,灌胃6周);糖尿病对照组(糖尿病组:链脲佐菌素(STZ),65mg/kg,腹腔注射);糖尿病+槲皮素1组(D+Q1:槲皮素,25mg/kg/天,溶于1ml 1%二甲基亚砜,STZ注射后灌胃6周);糖尿病+槲皮素2组(D+Q2:槲皮素,50mg/kg/天,溶于1ml 1%二甲基亚砜,STZ注射后灌胃6周)。测量体重、食物摄入量和饮水量。最终收集血浆和尿液样本以及肝脏和胰腺组织样本用于后续检测。
注射STZ导致血浆血糖水平升高、血浆胰岛素水平降低、肝功能障碍(AST、ALT和ALP活性水平升高,血浆总胆红素、胆固醇、低密度脂蛋白、甘油三酯水平升高,血浆总蛋白、白蛋白和高密度脂蛋白水平降低)、丙二醛水平升高、抗氧化酶(超氧化物歧化酶和过氧化氢酶)活性降低、谷胱甘肽(GSH)水平降低、apelin和TGF-β基因表达水平升高以及肝脏组织学破坏。所有这些变化均被槲皮素减轻。然而,D+Q2组的改善程度高于D+Q1组。
槲皮素可改善1型糖尿病后的肝功能,可能归因于脂质过氧化减少、抗氧化系统增强以及抑制apelin/TGF-β信号通路。